Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Label-Free but Still Constrained: Assessment of Global Proteomic Strategies for the Quantification of Hepatic Enzymes and Transporters

Jill Barber, Zubida M. Al-Majdoub, Narciso Couto, Areti-Maria Vasilogianni, Annika Tillmann, Sarah Alrubia, Amin Rostami-Hodjegan and Brahim Achour
Drug Metabolism and Disposition June 2022, 50 (6) 762-769; DOI: https://doi.org/10.1124/dmd.121.000780
Jill Barber
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jill Barber
Zubida M. Al-Majdoub
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zubida M. Al-Majdoub
Narciso Couto
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Narciso Couto
Areti-Maria Vasilogianni
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Areti-Maria Vasilogianni
Annika Tillmann
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Alrubia
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amin Rostami-Hodjegan
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amin Rostami-Hodjegan
Brahim Achour
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (J.B., Z.M.A.-M., N.C., A.-M.V., A.T., S.A., A.R.-H., B.A.) Simcyp Division, Certara, Sheffield, United Kingdom (A.R.-H.) and Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island (B.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brahim Achour
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Comparison of liver proteome measurements using three label-free methods. (A) Percentage of the measured total protein content relative to the nominal content (dashed line) analyzed by mass spectrometry. The amount was determined using the TPA, HiN [based on either myoglobin (MYG) or BSA as standards] and iBAQ (based on BSA). (B) Head-to-head comparison of average concentrations (of 2232 proteins) in 27 samples quantified by iBAQ (BSA) and TPA compared with HiN (BSA). (C) Correlation between mean concentrations of 57 key pharmacokinetic targets measured by TPA or iBAQ and mean abundances measured by HiN. The data show that TPA overestimates protein amounts compared with the HiN method, whereas HiN and iBAQ methods produce comparable results in most cases. The data also indicate that it is possible to estimate absolute abundances by iBAQ or TPA using conversion factors. Abundance is expressed in units of pmol mg−1 total protein.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Correlation between protein concentrations of key pharmacokinetic targets measured by iBAQ (blue) or TPA (orange) relative to HiN method in 27 liver samples. The data show examples of drug-metabolizing enzymes and transporters. BSA was used as a standard for HiN and iBAQ, and abundance was measured in units of pmol mg−1 total protein.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Correlation of protein concentrations of (A) cytochrome P450 and (B) UGT enzymes measured by HiN (red), iBAQ (blue), and TPA (orange) against functional activity in 27 liver samples. Activity was measured with metabolite formation assays against the substrates: phenacetin (CYP1A2), mephenytoin (CYP2B6), diclofenac (CYP2C9), mephenytoin (CYP2C19), bufuralol (CYP2D6), testosterone (CYP3A), β-estradiol (UGT1A1), chenodeoxycholic acid (UGT1A3), 5-hydroxytryptophol (UGT1A6), propofol (UGT1A9), zidovudine (UGT2B7) and S-oxazepam (UGT2B15). Abundance was measured in units of pmol mg−1 total protein; catalytic activity was measured in units of nmol metabolite min−1 mg−1 total protein.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Comparison of abundances of (A) cytochrome P450 and (B) UGT enzymes measured using label-free methods (HiN, iBAQ, and TPA) against targeted data. Ratios of label-free measurements relative to targeted data for (C) cytochrome P450 and (D) UGT enzymes. In (A) and (B), the whiskers represent the minimum-to-maximum range, the boxes represent the 25th and 75th percentiles, the lines represent the medians, and + signs represent the means. Comparisons based on a t test against targeted data are shown in black and against HiN measurements are shown in red. * P < 0.05, ** P < 0.01, and *** P < 0.001. In (C) and (D), the dashed lines denote the twofold range, and the percentages are the proportion of label-free measurements within twofold of targeted data. Abundance was measured in units of pmol mg−1 total protein.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Comparison of between-sample variability across 27 liver samples in the abundance of enzymes and transporters measured by HiN, iBAQ, and TPA, expressed as (A) fold difference (maximum-to-minimum ratio) and (B) percent CV (CV = SD × 100/mean). BSA was used as a standard for HiN and iBAQ.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    The total amount of protein in analyte estimated by the label-free quantification methods, averaged (± SD) over 27 samples.

    MethodEstimated Total Protein Content
    Nominal protein contenta16,667 pmol mg−1
    HiN based on BSA8916 ± 1775 pmol mg−1
    HiN based on myoglobin34,580 ± 5078 pmol mg−1
    iBAQ based on BSA19,265 ± 2937 pmol mg−1
    Total Protein Approach (TPA)24,513 ± 4620 pmol mg−1
    • aAmount estimated assuming an average analyte protein molecular mass of 60 kDa; units are pmol mg−1 total protein.

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Data -

      Supplemental Table 1. Demographic and clinical details of the donors of the 27 liver samples.

       Supplemental Table 2. Agreement in identification between technical replicates. 

      Supplemental Table 3. Similarity matrix between biological samples based on percent identical peptide (PIP).

      Supplemental Table 4. Abundance (in pmol mg-1) of cytochrome P450 enzymes, UGT enzymes, ABC transporters, and solute carriers using HiN with BSA as a standard.

      Supplemental Table 5. Abundance (in pmol mg-1) of cytochrome P450 enzymes, UGT enzymes, ABC transporters, and solute carriers using iBAQ with BSA as a standard.

      Supplemental Table 6. Abundance (in pmol mg-1) of cytochrome P450 enzymes, UGT enzymes, ABC transporters, and solute carriers using the TPA method.

      Supplemental Table 7. Effect of age, body mass index (BMI) and genotype on the abundance of enzymes and transporters measured using HiN, iBAQ and TPA label-free methods.

      Supplemental Figure 1. Relative abundance of (A) CYPs, (B) UGTs and (C) ABC transporters in human liver determined using either HiN, iBAQ or TPA.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 50 (6)
Drug Metabolism and Disposition
Vol. 50, Issue 6
1 Jun 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Label-Free but Still Constrained: Assessment of Global Proteomic Strategies for the Quantification of Hepatic Enzymes and Transporters
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Critique of Label-Free Proteomics of Pharmacokinetic Targets

Jill Barber, Zubida M. Al-Majdoub, Narciso Couto, Areti-Maria Vasilogianni, Annika Tillmann, Sarah Alrubia, Amin Rostami-Hodjegan and Brahim Achour
Drug Metabolism and Disposition June 1, 2022, 50 (6) 762-769; DOI: https://doi.org/10.1124/dmd.121.000780

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Critique of Label-Free Proteomics of Pharmacokinetic Targets

Jill Barber, Zubida M. Al-Majdoub, Narciso Couto, Areti-Maria Vasilogianni, Annika Tillmann, Sarah Alrubia, Amin Rostami-Hodjegan and Brahim Achour
Drug Metabolism and Disposition June 1, 2022, 50 (6) 762-769; DOI: https://doi.org/10.1124/dmd.121.000780
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolism of HSK3486 in humans
  • A MDCKII-MDR1-BCRP cell line to assess efflux at the BBB
  • Influence of CYP3A5 on vincristine disposition and toxicity
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics